Amicus Therapeutics (FOLD) EBIAT (2016 - 2025)
Historic EBIAT for Amicus Therapeutics (FOLD) over the last 17 years, with Q3 2025 value amounting to $17.3 million.
- Amicus Therapeutics' EBIAT rose 35718.53% to $17.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$14.1 million, marking a year-over-year increase of 8656.87%. This contributed to the annual value of -$56.1 million for FY2024, which is 6298.69% up from last year.
- Amicus Therapeutics' EBIAT amounted to $17.3 million in Q3 2025, which was up 35718.53% from -$24.4 million recorded in Q2 2025.
- Amicus Therapeutics' EBIAT's 5-year high stood at $17.3 million during Q3 2025, with a 5-year trough of -$85.3 million in Q1 2022.
- Moreover, its 5-year median value for EBIAT was -$43.2 million (2023), whereas its average is -$38.1 million.
- Over the last 5 years, Amicus Therapeutics' EBIAT had its largest YoY gain of 35718.53% in 2025, and its largest YoY loss of 5557.11% in 2025.
- Over the past 5 years, Amicus Therapeutics' EBIAT (Quarter) stood at -$83.3 million in 2021, then surged by 32.92% to -$55.9 million in 2022, then soared by 39.42% to -$33.8 million in 2023, then skyrocketed by 143.55% to $14.7 million in 2024, then grew by 17.42% to $17.3 million in 2025.
- Its EBIAT was $17.3 million in Q3 2025, compared to -$24.4 million in Q2 2025 and -$21.7 million in Q1 2025.